Sirius Pintuition

The value of soft tissue lesion localization

Value paper (short version)

001765v1.0 - EU EN (online)

The challenge of breast cancer

Breast cancer 1st most common disease in the world after lung cancer[1].

It's estimated that 1 in 8 women will develop breast cancer at some point in her life[2].

For smaller tumors and low-grade breast cancers, breast conserving surgery with radiation therapy is the standard of care[2]. The challenge is to localize the tumors and guide the surgical procedure. Wire-guided localization, the most commonly used technology, requires a strict coordination of radiology and surgery to be combined in one day, which often reduces radiology and operating room efficiency and negatively impacts the patient experience [3, 4].

Sirius Pintuition, a wire-free, radioactivity-free, hassle-free tumor localization system

The Sirius Pintuition marker-based localization system uses a percutaneously implanted seed inserted into the center of the breast lesion.

The Pintuition Seed may remain in place and be used for soft-tissue localization during up to 180 days [5]. By decoupling radiology and surgery, marker-based localization technologies like the Sirius Pintuition system increase the flexibility of timing and optimizes hospital resource utilization [6, 7, 8, 9].



Clinical performance of marker-based localization (MBL) technologies and Sirius Pintuition

MBL technologies have a good clinical track record, with ~13.6% positive resection margins (residual tumor tissue after resection) vs 14.4% or more for WGL technologies [8]. In early studies with a Sirius MBL technology, an improvement in margin status was found compared to WGL[9].
Sirius Pintuition like all MBL technologies has a favorable safety profile. No device-related serious adverse events have been reported with the system in clinical investigations [9, 10, 11, 12].
Seed migration is negligible and recorded seed retrieval rate is close to 100% [9, 10, 11, 12].

SiriusLink – A value program to optimize your surgical care pathway

Sirius Medical is committed to show value through the Value Based Healthcare Framework [14], which focuses on the value that a particular product, service, solution can create, in terms of improved outcomes for patients, cost of care efficiencies and additional benefits for stakeholders. Sirius Medical has created the SiriusLink service program which provide hospitals support for pathway discovery, pathway enhancement and implementation monitoring of Sirius Pintuition.



- **Outcomes:** Clinical performance and safety profile in the same league as WGL or better [8, 9, 13].
- **Cost of care:** By decoupling radiology and surgery schedules, Sirius Pintuition enables process improvements along the patient pathway [6, 15, 16, 17, 18].
- **Stakeholders' additional benefits:** Surgeons and radiologists express high satisfaction with the Sirius Pintuition system. Patient satisfaction scores are higher for MBL than for WGL [9,10].
- **Broader impact on society:** Technological advances such as Sirius Pintuition are driving the development of further innovations and applications to the benefit of the whole society. The efficiency gains with Sirius Pintuition experienced by users, organisations and patients, frees up time for productive activities across society.

The full white paper will give a more indepth view how Sirius Pintuition can bring value to your hospital within the Value Based Healthcare Framework.

Do you want to read the full white paper?

Reference

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;n/a(n/a). doi:https://doi.org/10.3322/caac.21660)

[2] Fajdic J, Djurovic D, Gotovac N, Hrgovic Z. Criteria and procedures for breast conserving surgery. Acta Inform Med. 2013;21(1):16-19. doi:10.5455/AIM.2013.21.16-19]

[3] H. A. Frank, F. M. Hall, and M. L. Steer, "Preoperative Localization of Nonpalpable Breast Lesions Demonstrated by Mammography," N. Engl. J. Med., vol. 295, no. 5, pp. 259–260, Jul. 1976.

[4] Cheang E, Ha R, Thornton CM, Mango VL. Innovations in image-guided preoperative breast lesion localization. The British Journal of Radiology. 2018 May;91(1085):20170740. DOI: 10.1259/bjr.20170740.

[5] Sirius Pintuition Seed Instructions For Use - EU EN

[6] Srour MK, Kim S, Amersi F, Giuliano AE, Chung A. Comparison of wire localization, radioactive seed, and Savi scout® radar for management of surgical breast disease. Breast J. 2020;26(3):406-413. doi:10.1111/tbj.13499

[7] Zacharioudakis K, Down S, Bholah Z, et al. Is the future magnetic? Magseed localisation for non palpable breast cancer. A multi-centre non randomised control study. Eur J Surg Oncol. 2019;45(11):2016-2021. doi:10.1016/j.ejso.2019.06.035

[8] Schermers, B. "Internal Sirius Pintuition Clinical Evaluation Report". Unpublished manuscript submitted to Notified Body. Apr, 2020

[9] Struik GM, Schermers B, et al. "Randomized Controlled Trial comparing Magnetic Marker Localization (MaMaLoc) with Wire Guided Localization in the treatment of early stage breast cancer". Unpublished manuscript under review. Apr, 2020

[10] Schermers B, van der Hage JA, Loo CE, et al. Feasibility of magnetic marker localisation for non-palpable breast cancer. Breast. 2017;33:50-56. doi:10.1016/j.breast.2017.03.003

[11] Bessems M, van Breest Smallenburg V, van Bebber I, et al. Safety and performance of Sirius Pintuition – a novel wire-free and non-radioactive localization system for breast cancer surgery. Eur J Surg Oncol. 2021;47(2):e1. doi:https://doi.org/10.1016/j.ejso.2020.11.148

[12]Bessems M, van Breest Smallenburg V, van Bebber I, et al. Safety and performance of Sirius Pintuition – a novel wire-free and non-radioactive localization system for breast cancer surgery. Eur J Surg Oncol. 2021;47(2):e1. doi:https://doi.org/10.1016/j.ejso.2020.11.148

[13] Micha AE, Sinnett V, Downey K, et al. Patient and clinician satisfaction and clinical outcomes of Magseed compared with wire-guided localisation for impalpable breast lesions. Breast Cancer. 2021;28(1):196-205. doi:10.1007/s12282-020-01149-1

[14] G. Gerecke et al., (2020) (available at http://image-src.bcg.com/Images/BCG-How-Procurement-Unlocks-Value-Based-Health-Care-Jan-2020-r_tcm9-238170.pdf).

[15] Zhang Y, Seely J, Cordeiro E, et al. Radioactive Seed Localization Versus Wire-Guided Localization for Nonpalpable Breast Cancer: A Cost and Operating Room Efficiency Analysis. Ann Surg Oncol. 2017;125. doi:10.1245/s10434-017-6084-z

[16] Sharek D, Zuley ML, Zhang JY, Soran A, Ahrendt GM, Ganott MA. Radioactive seed localization versus wire localization for lumpectomies: A comparison of outcomes. Am J Roentgenol. 2015;204(4):872-877. doi:10.2214/AJR.14.12743

[17] Lindenberg M, van Beek A, Retèl V, van Duijnhoven F, van Harten W. Early budget impact analysis on magnetic seed localization for non-palpable breast cancer surgery. PLoS One. 2020;15(5):e0232690. https://doi.org/10.1371/journal.pone.0232690

[18] Hayes MK, Frau M, Bloomquist E, Wright H. CLO20-037: Time is On Our Side: Concomitant Needle Biopsy and Wire-Free Localization of Axillary Lymph Nodes May Decrease Redundant Preoperative Needle Localization in BI-RADS 5, 6 Breast Cancer Patients. J Natl Compr Cancer Netw J Natl Compr Canc Netw. 2020;18(3.5).

info@sirius-medical.com High Tech Campus 41 5656 AE Eindhoven, The Netherlands